News | January 22, 2020

BioVentrix CE Mark Extended for Less Invasive Heart Failure Ventricular Enhancement

The BioVentrix Revivent TC transcatheter device anchors that help cinch the heart mucsle using a transcatheter procedure to treat left ventricular remodeling associated with heart failure following a heart attack. BioVentrix Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, announced the extension of its European CE mark approval for the Revivent TC Transcatheter Ventricular Enhancement System for heart failure to May 2024.

The BioVentrix Revivent TC transcatheter device anchors that help cinch the heart mucsle using a transcatheter procedure to treat left ventricular remodeling associated with heart failure following a heart attack.


January 22, 2020 – BioVentrix Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, announced the extension of its European CE mark approval for the Revivent TC Transcatheter Ventricular Enhancement System for heart failure to May 2024.

"The extension of our CE mark is not only an important milestone for the company, but also validates the need for a novel therapy for patients with left ventricular dysfunction who are among the estimated 10 million people in the European Union suffering from heart failure," said Kenneth Miller, president and CEO of BioVentrix. "It ensures that physicians will continue to have an important, less invasive therapeutic option for these patients.” 

The CE mark is issued by the European Commission and allows the device to be marketed throughout European Union (EU) member nations. BioVentrix received its initial CE mark in 2016.

Less Invasive Ventricular Enhancement, or LIVE therapy, uses the Revivent TC System to exclude scar tissue on the left ventricle that has occurred from a heart attack so the healthy portion of the heart can operate more efficiently. Micro-anchors are implanted and designed to remodel the heart to a more normal shape and size and reduce wall stress, which has been shown to improve blood flow throughout the body.[1]

Percutaneous coronary intervention (PCI), which implants a stent, is considered the standard of care for restoring blood flow to the heart after a heart attack. However, 50 percent of patients treated with PCI still develop large left ventricle (LV) scars,[2] which cause the heart to dilate. Enlarged LVs are associated with more severe heart failure symptoms, higher mortality and more frequent re-hospitalization.[3,4,5] Positive remodeling of the heart has been shown to improve LV function and heart failure symptoms.[6,7] The only currently available option is surgical ventricular remodeling, which is highly invasive.

The Revivent TC System is considered investigational and is not approved for sale in the United States.

 

Related BioVentrix Articles:

BioVentrix Announces Publication of Positive One-Year Outcomes for Revivent TC System

First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial

References:

1. Klein P, Ander SD, Wechsler A et al. Less invasive ventricular reconstruction for ischaemic heart failure. Eur J Heart Fail 2019;21(12):1638-1650.

2. Stone GW, Selker HP, Thiele H, et al. Relationship between infarct size and outcomes following primary PCI: patient-level analysis from 10 randomized trials. J Am Coll Cardiol 2016;67(14):1674-83.

3. Hamer AW, Takayama M, Abraham KA et al. End-systolic volume and long-term survival after coronary artery bypass graft surgery in patients with impaired left ventricular function. Circulation 1994;90:2899-904.

4. Axelrad JE, Pinsino A, Trinh PN et al. Limited usefulness of endoscopic evaluation in patients with continuous flow left ventricular assist devices and gastrointestinal bleeding. J Heart Lung Transplantation : the official publication of the International Society for Heart Transplantation 2018;37:723-732.

5. Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging 2011;4(1):98-108.

6. Athanasuleas CL, Buckberg GD, Stanley AW et al. Surgical ventricular restoration in the treatment of congestive heart failure due to post-infarction ventricular dilation. J Am Coll Cardiol 2004;44:1439-45.

7. Di Donato M, Frigiola A, Benhamouda M, Menicanti L. Safety and efficacy of surgical ventricular restoration in unstable patients with recent anterior myocardial infarction. Circulation 2004;110:II169-73.

Related Content

News | Cath Lab

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

Home May 31, 2022
Home
News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
News | Cath Lab

December 14, 2021 — RSIP Vision, a medical imaging company applying advanced artificial intelligence (AI) and computer ...

Home December 14, 2021
Home
Feature | Cath Lab

November 15, 2021 — RealView Imaging Ltd. recently received FDA 510(k) clearance for its Holoscope-i holographic system ...

Home November 15, 2021
Home
Subscribe Now